Department of Diabetes and Endocrinology, Royal Liverpool University Hospitals, Prescot Street, Liverpool, L7 8XP, UK.
Department of Primary Care and Public Health, School of Public Health, Imperial College London, St. Dunstan's Road, London, W6 8RP, UK.
J Diabetes Complications. 2017 Sep;31(9):1451-1457. doi: 10.1016/j.jdiacomp.2017.06.003. Epub 2017 Jun 15.
A clinical appraisal of existing scientific literature sought to assess the need for long-term prospective epidemiological studies to investigate an increased cancer risk of anti-hyperglycemic medication in type 2 diabetes.
A focus statement was formulated as: "With a higher risk of cancers in patients with type 2 diabetes, all anti-hyperglycemic drugs should undergo long-term, prospective epidemiological studies for cancer risks." Field surveys were sent to practicing physicians and endocrinologists to identify the currently prevalent level of acceptance of this statement. Subsequently, a meeting with a six-member panel of key opinion leaders was held to discuss published evidence in support and against the statement. This publication reviews the publications and discussion points brought forth in this meeting and their effect on statement acceptance by the panel.
Whereas the majority of field survey responders primarily agreed with the statement, panel members were divided in their statement support. This division remained intact after review of the literature.
While there was evidence that type 2 diabetes is associated with an increased risk of cancer, existing studies seemed insufficient to definitively demonstrate a link between cancer risk and use of specific anti-hyperglycemic therapies.
对现有科学文献进行临床评估，以评估是否需要进行长期前瞻性流行病学研究，以调查 2 型糖尿病患者使用抗高血糖药物的癌症风险增加问题。
制定了一个重点声明：“由于 2 型糖尿病患者的癌症风险较高，所有抗高血糖药物都应进行长期、前瞻性的流行病学研究，以评估癌症风险。”向执业医师和内分泌学家发送了实地调查，以确定对这一说法目前的普遍接受程度。随后，举行了一次由六名主要意见领袖组成的小组会议，讨论支持和反对该声明的已发表证据。本出版物审查了会议中提出的出版物和讨论要点，以及它们对小组对声明的接受程度的影响。
尽管大多数实地调查的答复者主要同意该声明，但小组成员在对该声明的支持上存在分歧。在审查文献后，这种分歧仍然存在。
虽然有证据表明 2 型糖尿病与癌症风险增加有关，但现有研究似乎不足以明确证明癌症风险与使用特定抗高血糖疗法之间存在联系。
